BACKGROUND/ OBJECTIVES:Microalbuminuria (MA) detects subjects at risk for cardiovascular disease (CVD) and chronic kidney disease (CKD) among diabetics, hypertensives and the general population. There is still a paucity of data on prevalence and risk factors for MA in the UK. We examined in a cross-sectional study, the prevalence and risk factors for MA in the general population of Sheffield, UK. METHODS: The study was conducted among participants of the Kidney Evaluation and Awareness Program in Sheffield (KEAPS), a population-based screening program for MA. The screening tools included a questionnaire collating information on demographics, lifestyle, medical and family history of diabetes mellitus, hypertension and CKD. MA measurements were obtained by immunonephelometry, and MA thresholds were defined using the albumin-creatinine ratio. RESULTS: The prevalence of MA was 7.1% in a random sample of a Sheffield-based population screened only once. The prevalence was 6.2% in the non-diabetic and non-hypertensive subjects. The prevalence of MA was only 1.3% in the subjects without any known risk factor, such as old age, diabetes, hypertension, obesity or CVD. The prevalence of MA could be overestimated as it was based on a single albumin-creatinine ratio testing. The independent predictor variables associated with the presence of MA in a mutually adjusted logistic regression model were: age (OR = 1.012, 95% CI: 1.00-1.02), diabetes (OR = 3.25, 95% CI: 1.30-8.13), obesity (OR = 4.09, 95% CI: 1.71-9.80) and family history of hypertension (OR = 1.87, 95% CI: 1.00-3.47). CONCLUSIONS: The main determinants of MA were increased age, diabetes, obesity and family history of hypertension. On the population level, obesity as a risk factor for MA is less well documented; in this study obesity had greater odds for MA than diabetes and hypertension.
RCT Entities:
BACKGROUND/ OBJECTIVES: Microalbuminuria (MA) detects subjects at risk for cardiovascular disease (CVD) and chronic kidney disease (CKD) among diabetics, hypertensives and the general population. There is still a paucity of data on prevalence and risk factors for MA in the UK. We examined in a cross-sectional study, the prevalence and risk factors for MA in the general population of Sheffield, UK. METHODS: The study was conducted among participants of the Kidney Evaluation and Awareness Program in Sheffield (KEAPS), a population-based screening program for MA. The screening tools included a questionnaire collating information on demographics, lifestyle, medical and family history of diabetes mellitus, hypertension and CKD. MA measurements were obtained by immunonephelometry, and MA thresholds were defined using the albumin-creatinine ratio. RESULTS: The prevalence of MA was 7.1% in a random sample of a Sheffield-based population screened only once. The prevalence was 6.2% in the non-diabetic and non-hypertensive subjects. The prevalence of MA was only 1.3% in the subjects without any known risk factor, such as old age, diabetes, hypertension, obesity or CVD. The prevalence of MA could be overestimated as it was based on a single albumin-creatinine ratio testing. The independent predictor variables associated with the presence of MA in a mutually adjusted logistic regression model were: age (OR = 1.012, 95% CI: 1.00-1.02), diabetes (OR = 3.25, 95% CI: 1.30-8.13), obesity (OR = 4.09, 95% CI: 1.71-9.80) and family history of hypertension (OR = 1.87, 95% CI: 1.00-3.47). CONCLUSIONS: The main determinants of MA were increased age, diabetes, obesity and family history of hypertension. On the population level, obesity as a risk factor for MA is less well documented; in this study obesity had greater odds for MA than diabetes and hypertension.